drugset / Trial / NCT02584725

Tranexamic Acid Dosing for Total Joint Arthroplasty

NCT02584725

Phase 4 Completed 84 enrolled Columbia University
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the effect of increasing doses of tranexamic acid (TXA) on limiting blood loss during total knee and total hip arthroplasty as defined by a change in hemoglobin from pre-operative baseline to the first post-operative day.

Timeline

Start
2014-12
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 5 mg/kg Intravenous
Comparator Tranexamic Acid Small molecule 10 mg/kg Intravenous
Comparator Tranexamic Acid Small molecule 15 mg/kg Intravenous

Indications